US-based Healthtech company providing remote patient monitoring solutions for COPD patients.
In September of 2024, Gilde portfolio company Spire Health merged with Wellinks, creating the industry leader in predictive patient care for cardiopulmonary disease.
Wellinks provides a fully virtual , cardiopulmonary clinical care model for patients, complementing the patient’s current in person care team. With the addition of Spire’s passive sensor technology for predicting high-cost hospital exacerbations, Wellinks is able to care for at risk cardiopulmonary patients, accurately predicting deterioration for the patient, providing early intervention for optimal patient outcomes and lowering cost for the healthcare system overall (Spire previously published a study demonstrating a 65% reduction in hospitalizations due to COPD exacerbations).
Cardiopulmonary disease, including COPD and CHF, impacts over 20M people in the US alone, representing one of the greatest care and cost challenges for the current healthcare system. Wellinks’ approach holds great potential for reducing costs and improving outcomes for payers and providers in both value-based-care and fee-for-service settings.
Gilde Healthcare invested in Spire in 2021 to support the company’s commercial expansion, innovation, and evidence generation with the goal of bringing Spire’s RPM solutions to more pulmonologists and patients.